Roivant Sciences Ltd. - Common Shares (ROIV)

Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology.

Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials.

This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets.

TTM Technologies supplies advanced printed circuit boards and RF components for high-reliability applications across diverse industries.

American Healthcare REIT manages a diverse portfolio of healthcare properties across the U.S. and U.K., serving institutional tenants.

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]

In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500. This rally, which reached its zenith on January 22, 2026, represents the longest period of small-cap dominance since

Roivant (NASDAQ: ROIV) outlined accelerated timelines and expanded commercial ambitions for several late-stage programs.

Roivant (ROIV) Q2 2026 Earnings Call Transcript

Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study, the company said.

The drugmaker just cleared a major hurdle to winning FDA approval for a promising autoimmune disease drug.

Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

The company is working on a treatment for an autoimmune disease that affects the skin and muscles.

Investors were in a forgiving mood after Monday's dispiriting earnings release.

The distinctive biotech wasn't a sector favorite as the trading week began.